Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Nature Publishing Group full text link Nature Publishing Group Free PMC article
Full text links

Actions

Share

.2007 Jul 16;97(2):238-46.
doi: 10.1038/sj.bjc.6603820. Epub 2007 Jun 19.

Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification

Affiliations

Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification

G Schleiermacher et al. Br J Cancer..

Abstract

Whereas neuroblastoma (NB) with MYCN amplification presents a poor prognosis, no single marker allows to reliably predict outcome in tumours without MYCN amplification. We report here an extensive analysis of 147 NB samples at diagnosis, without MYCN amplification, by chromosomal comparative genomic hybridisation (CGH), providing a comprehensive overview of their genomic imbalances. Comparative genomic hybridisation profiles showed gains or losses of entire chromosomes (type 1) in 71 cases, whereas partial chromosome gains or losses (type 2), including gain involving 17q were observed in 68 cases. Atypical profiles were present in eight cases. A type 1 profile was observed more frequently in localised disease (P<0.0001), and in patients of less than 12 months at diagnosis (P<0.0001). A type 2 genomic profile was associated with a higher risk of relapse in the overall population (log-rank test; P<0.0001), but also in the subgroup of patients with localised disease (log-rank test, P=0.007). In multivariate analysis, the genomic profile was the strongest independent prognostic factor. In conclusion, the genomic profile is of prognostic impact in patients without MYCN amplification, making it a help in the management of low-stage NB. Further studies using higher-resolution CGH are needed to better characterise atypical genomic alterations.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Diagram showing gains and losses detected by chromosomal CGH in tumours with a type 1 genomic profile, characterised by numerical chromosome alterations. Losses are indicated by a bar on the left and gains by a bar on the right of each chromosome ideogram. Each bar represents an alteration observed in one tumour.
Figure 2
Figure 2
Diagram showing gains and losses detected by chromosomal CGH in tumours with a type 2 genomic profile, characterised by segmental chromosome alterations. Losses are indicated by a bar on the left and gains by a bar on the right of each chromosome ideogram. Each bar represents an alteration observed in one tumour. (A) Segmental alterations observed in tumours without chromosome 1p deletions (type 2a). (B) Segmental alterations observed in tumours with chromosome 1p deletions (type 2b).
Figure 3
Figure 3
Survival curves of 139 neuroblastoma patients. (A) Event-free survival of all patients. (B) Overall survival of all patients. (C) Event-free survival according to stage at diagnosis. (D) Event-free survival according to age at diagnosis.
Figure 4
Figure 4
Survival curves according to genetic markers. (A) Event-free survival according to chromosome 11q status. (B) Event-free survival according to chromosome 17q status. (C) Event-free survival according to the genomic profile, type 1 referring to numerical alterations, and type 2a and 2b referring to structural chromosome alterations without or with chromosome 1p loss. (D) Metastasis-free survival according to the genomic profile.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abel F, Ejeskar K, Kogner P, Martinsson T (1999) Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24. Br J Cancer 81: 1402–1409 - PMC - PubMed
    1. Ambros PF, Ambros IM, Kerbl R, Luegmayr A, Rumpler S, Ladenstein R, Amann G, Kovar H, Horcher E, De Bernardi B, Michon J, Gadner H (2001) Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas. Med Pediatr Oncol 36: 1–4 - PubMed
    1. Ambros IM, Benard J, Boavida M, Bown N, Caron H, Combaret V, Couturier J, Darnfors C, Delattre O, Freeman-Edward J, Gambini C, Gross N, Hattinger CM, Luegmayr A, Lunec J, Martinsson T, Mazzocco K, Navarro S, Noguera R, O'Neill S, Potschger U, Rumpler S, Speleman F, Tonini GP, Valent A, Van Roy N, Amann G, De Bernardi B, Kogner P, Ladenstein R, Michon J, Pearson AD, Ambros PF (2003) Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 21: 2077–2084 - PubMed
    1. Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, Brodeur GM, Cohn SL, Matthay KK, Maris JM, Children's Oncology Group (2005) Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353: 2243–2253 - PubMed
    1. Bilke S, Chen QR, Westerman F, Schwab M, Catchpoole D, Khan J (2005) Inferring a tumor progression model for neuroblastoma from genomic data. J Clin Oncol 23: 7322–7331 - PubMed

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full text links
Nature Publishing Group full text link Nature Publishing Group Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp